• Mashup Score: 10
    Measuring US Maternal Mortality - 6 month(s) ago

    This Viewpoint discusses the importance of collaboration among the agencies responsible for documenting rates of maternal mortality to ensure more accurate, reliable, and timely estimates.

    Source: jamanetwork.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of MonicaGandhi9
      MonicaGandhi9

      RT @CarlosdelRio7: Measuring US Maternal Mortality https://t.co/16GASaGSnK The 2021 rate from the NVSS was 32.9 maternal deaths per 100 000…

  • Mashup Score: 1
    Dare to Dream Project: Treating Kids with Blood Cancer | LLS - 6 month(s) ago

    We’re daring to improve the quality of life for every child with blood cancer, daring to dream of them thriving. Find out more about the Leukemia and Lymphoma Society!

    Source: www.lls.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of LLSusa
      LLSusa

      Our Dare to Dream Summit attendees listen in as LLS President & CEO E. Anders Kolb, M.D. discusses our shared vision for a future with better treatment and care for kids with blood cancer. Check out more about the Dare to Dream Project 👉 https://t.co/sQoQqTSRNB https://t.co/5Kivkvyq57

  • Mashup Score: 1
    stats - 6 month(s) ago

    Learn more about the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).

    Source: www.cdc.gov
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of MonicaGandhi9
      MonicaGandhi9

      PrEP PRESCRIPTIONS: Given to 36% of those who need pre-exposure prophylaxis (PrEP) to prevent HIV in 2022 (up from 12% before so increasing but still not high enough) - CDC data from US https://t.co/Y6919g0ueT

  • Mashup Score: 10
    Systematic Assessment of Shock Severity in Postoperative Cardiac Surgery Patients: - 6 month(s) ago

    Abstract Background The Society for Cardiovascular Angiography and Interventions (SCAI) shock classification has been shown to provide robust mortality risk stratification in a variety of cardiovas…

    Source: www.jacc.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of JACCJournals
      JACCJournals

      The @SCAI shock classification effectively risk-stratifies cardiac surgery #ICU patients for hospital mortality, postoperative complications & organ dysfunction, thus proving its clinical usefulness in the field of #cvSurg. https://t.co/FwoRt30Y94 #JACC #CardioTwitter… https://t.co/ZdICcF5TtY https://t.co/t0KlIAnf0j

  • Mashup Score: 6
    Dare to Dream Project: Treating Kids with Blood Cancer | LLS - 6 month(s) ago

    We’re daring to improve the quality of life for every child with blood cancer, daring to dream of them thriving. Find out more about the Leukemia and Lymphoma Society!

    Source: www.lls.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of LLSusa
      LLSusa

      As part of our Dare to Dream Project, PedAL, the first-of-its-kind global master clinical trial, matches patients to treatment based on their cancer's unique tumor biology. Find out more about PedAL and the Dare to Dream Project 👉 https://t.co/6Ok66xfrQ4

  • Mashup Score: 0
    Methodological Concerns in PARP Inhibitor Trials Leave Unanswered Questions for mCRPC - 6 month(s) ago

    Home > CRPC > Methodological Concerns in PARP Inhibitor Trials Leave Unanswered Questions for mCRPC Daniel A. González-Padilla, of the Clínica Universidad de Navarra in Spain, shares his thoughts on the methodological concerns of TRITON3 and PROfound for rucaparib and olaparib in treating mCRPC, including prior treatments, control arms, postprotocol treatments, and inappropriate crossover. He also elaborates on what further overall survival data or other survival data are needed before rucaparib or

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      Do you agree with @Daniel_Urologia that crossover and postprotocol treatments limit the actionability of TRITON3 and PROfound in metastatic #prostatecancer? Hear what he has to say https://t.co/reHagTB01p @josedsh @EUplatinum https://t.co/yvQH33MP8N

Load More